title: Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo.
abstract: OBJECTIVE
  Lymph cancers are heterogeneous malignancies of the hematopoietic and lymphoid tissues. Doxorubicin (DOX) and vincristine (VCR) are commonly used anti-cancer chemotherapeutic drugs, but their clinical uses are associated with dose-limiting systemic toxicity.
  
  
  METHODS
  In the present study, DOX and VCR were encapsulated into nanostructured lipid carriers (NLCs) and used them to treat B-cell lymphoma cells through the targeted delivery of DOX and VCR to lymph cancer animal model.
  
  
  RESULTS
  DOX and VCR encapsulated NLCs (DOX/VCR NLCs) demonstrated controlled drug release under physiological conditions. In addition, DOX/VCR NLCs exhibited the highest cytotoxicity and synergistic effect of two drugs in B-cell lymphoma cells and the best anti-tumor effect in vivo.
  
  
  CONCLUSIONS
  DOX/VCR NLCs were proved to be more efficacious than the equivalent dose of free DOX and single drug (DOX or VCR) formulation in vitro and in vivo, and significantly reduced the drug-associated systemic toxicity.
authors.affiliation: a Department of Hematology and.
authors.forename: Xiaoyuan
authors.initials: X
authors.lastname: Dong
authors.affiliation: a Department of Hematology and.
authors.forename: Wen
authors.initials: W
authors.lastname: Wang
authors.affiliation: b Department of Gastrointestinal Surgery , Qilu Hospital of Shandong University , Ji'nan , Shandong , P.R. China .
authors.forename: Hui
authors.initials: H
authors.lastname: Qu
authors.affiliation: c Department of General Surgery , People's Hospital of Laiwu City Laicheng District , Laiwu , Shandong , P.R. China , and.
authors.forename: Dong
authors.initials: D
authors.lastname: Han
authors.affiliation: d Department of General Surgery , People's Hospital of Weifang City Fangzi District , Weifang , Shandong , P.R. China.
authors.forename: Junmin
authors.initials: J
authors.lastname: Zheng
authors.affiliation: b Department of Gastrointestinal Surgery , Qilu Hospital of Shandong University , Ji'nan , Shandong , P.R. China .
authors.forename: Guorui
authors.initials: G
authors.lastname: Sun
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D004337:Drug Carriers; D065546:Drug Liberation; D018432:Drug Resistance, Multiple; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008196:Lymph / Q000737:chemistry* / Q000187:drug effects*; D049329:Nanostructures / Q000737:chemistry*; D014750:Vincristine / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008055:Lipids; D014750:Vincristine; D004317:Doxorubicin
keywords: B-cell lymphoma; lymph cancer; nanostructured lipid carriers; synergistic therapy; targeted delivery